518 related articles for article (PubMed ID: 28820437)
1. Are Astrocytes the Predominant Cell Type for Activation of Nrf2 in Aging and Neurodegeneration?
Liddell JR
Antioxidants (Basel); 2017 Aug; 6(3):. PubMed ID: 28820437
[TBL] [Abstract][Full Text] [Related]
2. The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration.
Johnson JA; Johnson DA; Kraft AD; Calkins MJ; Jakel RJ; Vargas MR; Chen PC
Ann N Y Acad Sci; 2008 Dec; 1147():61-9. PubMed ID: 19076431
[TBL] [Abstract][Full Text] [Related]
3. Modulation of mitochondrial dysfunction in neurodegenerative diseases via activation of nuclear factor erythroid-2-related factor 2 by food-derived compounds.
Denzer I; Münch G; Friedland K
Pharmacol Res; 2016 Jan; 103():80-94. PubMed ID: 26626189
[TBL] [Abstract][Full Text] [Related]
4. Nrf2/ARE Signaling Pathway: Key Mediator in Oxidative Stress and Potential Therapeutic Target in ALS.
Petri S; Körner S; Kiaei M
Neurol Res Int; 2012; 2012():878030. PubMed ID: 23050144
[TBL] [Abstract][Full Text] [Related]
5. Role of Nrf2 in aging, Alzheimer's and other neurodegenerative diseases.
George M; Tharakan M; Culberson J; Reddy AP; Reddy PH
Ageing Res Rev; 2022 Dec; 82():101756. PubMed ID: 36243357
[TBL] [Abstract][Full Text] [Related]
6. Nrf2--a therapeutic target for the treatment of neurodegenerative diseases.
Johnson DA; Johnson JA
Free Radic Biol Med; 2015 Nov; 88(Pt B):253-267. PubMed ID: 26281945
[TBL] [Abstract][Full Text] [Related]
7. Role of the Keap1/Nrf2 pathway in neurodegenerative diseases.
Yamazaki H; Tanji K; Wakabayashi K; Matsuura S; Itoh K
Pathol Int; 2015 May; 65(5):210-9. PubMed ID: 25707882
[TBL] [Abstract][Full Text] [Related]
8. Antioxidant and Anti-inflammatory Effect of Nrf2 Inducer Dimethyl Fumarate in Neurodegenerative Diseases.
Scuderi SA; Ardizzone A; Paterniti I; Esposito E; Campolo M
Antioxidants (Basel); 2020 Jul; 9(7):. PubMed ID: 32708926
[TBL] [Abstract][Full Text] [Related]
9. Electrophilic nitro-fatty acids prevent astrocyte-mediated toxicity to motor neurons in a cell model of familial amyotrophic lateral sclerosis via nuclear factor erythroid 2-related factor activation.
Diaz-Amarilla P; Miquel E; Trostchansky A; Trias E; Ferreira AM; Freeman BA; Cassina P; Barbeito L; Vargas MR; Rubbo H
Free Radic Biol Med; 2016 Jun; 95():112-20. PubMed ID: 27012417
[TBL] [Abstract][Full Text] [Related]
10. Targeting crosstalk between Nuclear factor (erythroid-derived 2)-like 2 and Nuclear factor kappa beta pathway by Nrf2 activator dimethyl fumarate in epileptogenesis.
Singh N; Vijayanti S; Saha L
Int J Neurosci; 2018 Oct; 128(10):987-994. PubMed ID: 29447051
[TBL] [Abstract][Full Text] [Related]
11. Targeting Nrf2 to Suppress Ferroptosis and Mitochondrial Dysfunction in Neurodegeneration.
Abdalkader M; Lampinen R; Kanninen KM; Malm TM; Liddell JR
Front Neurosci; 2018; 12():466. PubMed ID: 30042655
[TBL] [Abstract][Full Text] [Related]
12. Activation of the astrocytic Nrf2/ARE system ameliorates the formation of demyelinating lesions in a multiple sclerosis animal model.
Draheim T; Liessem A; Scheld M; Wilms F; Weißflog M; Denecke B; Kensler TW; Zendedel A; Beyer C; Kipp M; Wruck CJ; Fragoulis A; Clarner T
Glia; 2016 Dec; 64(12):2219-2230. PubMed ID: 27641725
[TBL] [Abstract][Full Text] [Related]
13. Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).
Bresciani A; Missineo A; Gallo M; Cerretani M; Fezzardi P; Tomei L; Cicero DO; Altamura S; Santoprete A; Ingenito R; Bianchi E; Pacifici R; Dominguez C; Munoz-Sanjuan I; Harper S; Toledo-Sherman L; Park LC
Arch Biochem Biophys; 2017 Oct; 631():31-41. PubMed ID: 28801166
[TBL] [Abstract][Full Text] [Related]
14. Review of molecular mechanisms involved in the activation of the Nrf2-ARE signaling pathway by chemopreventive agents.
Giudice A; Arra C; Turco MC
Methods Mol Biol; 2010; 647():37-74. PubMed ID: 20694660
[TBL] [Abstract][Full Text] [Related]
15. Cerebrovascular and Neurological Disorders: Protective Role of NRF2.
Sivandzade F; Bhalerao A; Cucullo L
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336872
[TBL] [Abstract][Full Text] [Related]
16. Shaping the Nrf2-ARE-related pathways in Alzheimer's and Parkinson's diseases.
Fão L; Mota SI; Rego AC
Ageing Res Rev; 2019 Sep; 54():100942. PubMed ID: 31415806
[TBL] [Abstract][Full Text] [Related]
17. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.
Linker RA; Lee DH; Ryan S; van Dam AM; Conrad R; Bista P; Zeng W; Hronowsky X; Buko A; Chollate S; Ellrichmann G; Brück W; Dawson K; Goelz S; Wiese S; Scannevin RH; Lukashev M; Gold R
Brain; 2011 Mar; 134(Pt 3):678-92. PubMed ID: 21354971
[TBL] [Abstract][Full Text] [Related]
18. Dimethyl fumarate attenuates reactive microglia and long-term memory deficits following systemic immune challenge.
Paraiso HC; Kuo PC; Curfman ET; Moon HJ; Sweazey RD; Yen JH; Chang FL; Yu IC
J Neuroinflammation; 2018 Mar; 15(1):100. PubMed ID: 29598822
[TBL] [Abstract][Full Text] [Related]
19. Contribution of the Nrf2 Pathway on Oxidative Damage and Mitochondrial Failure in Parkinson and Alzheimer's Disease.
Villavicencio Tejo F; Quintanilla RA
Antioxidants (Basel); 2021 Jul; 10(7):. PubMed ID: 34356302
[TBL] [Abstract][Full Text] [Related]
20. The Nrf2-ARE Signalling pathway: promising drug target to combat oxidative stress in neurodegenerative disorders.
van Muiswinkel FL; Kuiperij HB
Curr Drug Targets CNS Neurol Disord; 2005 Jun; 4(3):267-81. PubMed ID: 15975029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
